| Synonym |
| Thai / English name |
Part Used : ไม่ระบุActivity : CYP1A1 INDUCTIONSolvent/Active Compound : kaempferolType of experiment : in vitroType of animal : -Type of study : -N(Total) : -N(Treatment) : -Sex : -Age : -Route : -Dose/Conc.(herb) : kaempferol 6.3 mcg/mLDuration : MCF-10A cells were treated with kaempferol for 48 hType of interaction : PharmacokineticsInteraction with drug : -Dose/Conc.(drug) : -Result : NegativeRemark : Result: Kaempferol and isorhamnetin decreased basal CYP1B1 mRNA expression by 65% and 57%, respectively, but these compounds did not alter CYP1A1 mRNA expression.Note : Solvent/compound: Ginkgo biloba extract contained 6.2% w/w terpene trilactones, consisting of bilobalide (2.8%), ginkgolide A (1.1%), ginkgolide B (0.3%), ginkgolide C (1.4%), and ginkgolide J (0.6%). It also contained 21% w/w flavonols (as sum of the aglycone and glycosides), consisting of quercetin (10.6%), kaempferol (6.3%), and isorhamnetin (4.1%).
Part Used : ไม่ระบุActivity : CYP1A1 INDUCTIONSolvent/Active Compound : IsorhamnetinType of experiment : in vitroType of animal : -Type of study : -N(Total) : -N(Treatment) : -Sex : -Age : -Route : -Dose/Conc.(herb) : isorhamnetin 4.1 mcg/mLDuration : MCF-10A cells were treated with isorhamnetin for 48 hType of interaction : PharmacokineticsInteraction with drug : -Dose/Conc.(drug) : -Result : NegativeRemark : Result: Kaempferol and isorhamnetin decreased basal CYP1B1 mRNA expression by 65% and 57%, respectively, but these compounds did not alter CYP1A1 mRNA expression.Note : Solvent/compound: Ginkgo biloba extract contained 6.2% w/w terpene trilactones, consisting of bilobalide (2.8%), ginkgolide A (1.1%), ginkgolide B (0.3%), ginkgolide C (1.4%), and ginkgolide J (0.6%). It also contained 21% w/w flavonols (as sum of the aglycone and glycosides), consisting of quercetin (10.6%), kaempferol (6.3%), and isorhamnetin (4.1%).
Part Used : -Activity : CYP1A1 INDUCTIONSolvent/Active Compound : The standard Ginkgo biloba extraction (EGB761)Type of experiment : in vivoType of animal : ratType of study : -N(Total) : -N(Treatment) : -Sex : -Age : -Route : Oral administrationDose/Conc.(herb) : EGB761 10 mg/kg/dayDuration : 10 daysType of interaction : PharmacokineticsInteraction with drug : Propranolol*/Propanolol/Beta-propranololDose/Conc.(drug) : -Result : EquivocalRemark :Note : - A single oral dose of propranolol (10 mg/kg) was administered on day 11. - Data incomplete
Part Used : -Activity : CYP1A1 INDUCTIONSolvent/Active Compound : The standard Ginkgo biloba extraction (EGB761)Type of experiment : in vivoType of animal : ratType of study : -N(Total) : -N(Treatment) : -Sex : -Age : -Route : Oral administrationDose/Conc.(herb) : EGB761 100 mg/kg/dayDuration : 10 daysType of interaction : PharmacokineticsInteraction with drug : Propranolol*/Propanolol/Beta-propranololDose/Conc.(drug) : -Result : PositiveRemark : Pretreatment of EGB761 at 100 mg/kg for 10 days significantly reduced the area uder the plasma concentration time curve (AUC) and maximum plasma concentration (Cmax) of propranolol, whereas those values of N-desisopropylpropranolol (NDP) were significantly increased.Note : - A single oral dose of propranolol (10 mg/kg) was administered on day 11. - Data incomplete
